Outcomes of patients treated with fluticasone propionate or montelukast sodium.
The authors conducted a retrospective database study of patients with asthma (age range, 6-55 yr) who initiated fluticasone propionate or montelukast sodium treatment between an index period of July 1998 and June 1999. All patients were observed for 12 months before and after the index period. Changes in asthma-related hospitalizations, emergency department visits, oral corticosteroid use, and short-acting beta-agonist use were analyzed. The odds of postindex asthma-related events were estimated. In multivariate analysis, use of a short-acting beta agonist (SABA) was significantly associated with fluticasone treatment (odds ratio [OR], 1.65; 95% confidence interval [CI], 1.21-2.26) and preindex use of SABAs (OR, 1.84; 95% CI, 1.34-2.53). In this managed care population, fluticasone and montelukast provided similar effectiveness.
Allen-Ramey
Felicia C
FC
Department of Epidemiology, Merck and Company, West Point, Pennsylvania, USA. felicia_ramey@merck.com
Duong
Phong T
PT
Goodman
David C
DC
Sajjan
Shiva G
SG
Nelsen
Linda M
LM
Markson
Leona
L
D000085:Acetates / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000730:Androstadienes / Q000627:therapeutic use*; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy*; D002648:Child; D003521:Cyclopropanes; D004636:Emergency Service, Hospital / Q000706:statistics & numerical data; D005260:Female; D000068298:Fluticasone; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D017063:Outcome Assessment, Health Care; D011804:Quinolines / Q000627:therapeutic use*; D012189:Retrospective Studies; D013440:Sulfides; D014481:United States
D000085:Acetates; D000730:Androstadienes; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D000068298:Fluticasone; C093875:montelukast